Cantor Fitzgerald upgraded shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) from a neutral rating to an overweight rating in a research note published on Wednesday morning, Marketbeat reports.

AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today announced the appointment of Matthew Hawryluk, Ph.D., MBA, as Chief ...

Baird downgraded Leap Therapeutics (LPTX) to Neutral from Outperform with a price target of $1.25, down from $9, after the ...

Intellia Therapeutics, Inc. shares declined over 5% on Monday morning after Morgan Stanley downgraded the stock to ‘Equal ...

Morgan Stanley downgraded Intellia Therapeutics (NTLA) to Equal Weight from Overweight with a price target of $11, down from $56. The firm now ...

Equities research analysts at Leerink Partnrs boosted their FY2024 earnings estimates for Beam Therapeutics in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M ...

The stock of Vertex Pharmaceuticals Incorporated VRTX has declined almost 13% in the past six months. A key reason for the stock price decline was unimpressive data from a phase II study on its key ...

Camille Regli, a beloved mother, grandmother, friend, and artist, passed away peacefully at the age of 86 on January 14, 2025 ...

This was the case for one Briton who experienced months of severe health complications before finally receiving a diagnosis of vitamin B12 deficiency, despite making multiple visits to her GP. Taking ...

In the largest deal of 2024 (Table 1), major CDMO player Catalent was acquired by Novo Holdings — an investment company that manages assets for the Novo Nordisk Foundation — for $16.5 billion.

Additionally, Wave Life Sciences plans to share multi-dose data from the RestorAATion-2 study of WVE-006 in alpha-1-antitrypsin deficiency, along with new preclinical data from their RNA editing ...

In addition, NTLA-3001 was being targeted at alpha-1 antitrypsin deficiency (AATD), which is expected to have a global market of $10B by 2033. So, I understand if investors are becoming concerned ...